reports
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 202...
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency ba...
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024 SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location: • Date:Thursday, April 25, 2024 • Time:1:30 p.m. PDT ...
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis 36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and othe...
Introducing the AirFit F40: Experience Unprecedented Freedom with the ...
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask.Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred positio...
ResMed Inc: 1 director
A director at ResMed Inc sold 23,535 shares at 182.664USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers ...
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapyPart of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: ...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 20...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20%Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023. Second Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 12% to $1.2 billion; up 1...
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 20...
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024 SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:• Date:Wednesday, January 24, 2024• Time:1:30 ...
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthca...
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay will be ...
ResMed Notifies Customers About Updated Instructions and Labeling for ...
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. This voluntary field correction does not require a r...
ResMed Secures Significant Victory in Patent Fight Against New York Un...
ResMed Secures Significant Victory in Patent Fight Against New York University SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims New York University (NYU) asserted against ResMed, based on seven NYU patents. In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware. NYU’s complaint alleged that the AutoSetTM and AutoRampTM features of ResMed’s AirSenseTM 1...
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Milli...
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally Published in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open, t...
ResMed Adopts New Operating Model to Accelerate Long-term Growth
ResMed Adopts New Operating Model to Accelerate Long-term Growth Justin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective immediately.Rob Douglas, President and Chief Operating Officer, to retire January 1, 2024. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the gl...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 202...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024 Year-over-year revenue grows 16%, operating profit up 5%, non-GAAP operating profit up 10%Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2023. First Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 16% to $1.1 billion; up 15% on...
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 202...
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023 SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:•Date:Thursday, October 26, 2023•Time:1:30 p.m. PD...
ResMed Announces Participation in Upcoming Conferences
ResMed Announces Participation in Upcoming Conferences SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences. Mick Farrell, chief executive officer and chair of the board, and Brett Sandercock, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, beginning at approximately 10:50 a.m. (Eastern Daylight Time) at the Sheraton New York Times Square in New York, NY. Rob Douglas, president and chief operating ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TGI TRIUMPH GROUP INC.
TFX TELEFLEX INCORPORATED
STAA STAAR SURGICAL CO.
SNE. SONY CORP. (ADS)
SLAB SILICON LABORATORIES INC.
SEE SEALED AIR CORPORATION
SEDG SOLAREDGE TECHNOLOGIES INC.
RVNC REVANCE THERAPEUTICS INC.
RMD RESMED INC.
MMSI MERIT MEDICAL SYSTEMS INC.
KHC KRAFT HEINZ COMPANY
ICUI ICU MEDICAL INC.
HMC HARMONIC
GIS GENERAL MILLS INC.
DIOD DIODES INCORPORATED
BLFS BIOLIFE SOLUTIONS INC
AVD AMERICAN VANGUARD
ODEL.N0000 ODEL PLC
ENPH ENPHASE ENERGY INC.
FMC FMC CORPORATION
VMI VALMONT INDUSTRIES INC.
PI IMPINJ INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
GTES GATES INDUSTRIAL CORP
TMDX TRANSMEDICS GROUP
CTVA CORTEVA INC
KROS KEROS THERAPEUTICS
LAC. LITHIUM AMERICAS CORP
TMCI TREACE MED CONCEPTS INC
PLL PIEDMONT LITHIUM INC
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023 Year-over-year revenue grows 23%, operating profit up 8%, non-GAAP operating profit up 13%Quarterly dividend increases 9% to $0.48 per share Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2023. Fourth Quarter 2023 HighlightsAll comparisons are to the prior year period Revenue increased by 23% to $1.1 billion; up 23% on a constant cur...
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023 SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location: • Date: Thursday, August 3, 2023 • Time:1:30 p.m. PD...
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory C...
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatmentDiagnostic management platform is upstream of and complementary to ResMed’s current post-testing AirView and Brightree offeringsSomnoware platform will remain an open platform to enable sleep labs, pulmonary function testing facilities, and physicians to view results from various testing solutions and help diagnosed patients get o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.